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Patient selection for extracorporeal 
co2 removal: a task as challenging 
as for ecMo therapy 
Dear editor,
We would like to thank Pettenuzzo and Del sorbo 
for their insightful comment 1 on our article exploring 
the feasibility of low flow veno-venous extracorporeal 
co2 removal (ecco2r) in acute hypercapnic respira-
tory failure.2
the patient population included in our study re-
flects the typical case mix present in a universitary in-
tensive care unit affiliated with a lung transplantation 
unit. Despite the resulting population heterogeneity, 
this approach was chosen in order to enable a feasi-
bility assessment of ecco2r that is closely rooted in 
reality, as well as verification in a broad population 
of our preliminary indications for therapy that were, 
based on previous literature, focused on parameters re-
garding respiratory failure.3 We were thus able to iden-
tify a subpopulation where further risk stratification 
is necessary to avoid treatment futility, namely me-
chanically ventilated patients mainly suffering from 
acute respiratory distress syndrome (arDs). Based 
on these results, as is stated in our article, we agree 
with Pettenuzzo and Del sorbo that the indications for 
ecco2R need to be refined – especially in patients 
whose outcome depend on successful bridging to re-
covery. the PreserVe score as a tool for assessment 
of recovery potential in arDs patients where veno-ve-
nous extracorporeal membrane oxygenation (ecMo) 
therapy is considered,4 has recently been validated in 
our population of arDs patients treated with ecMo.5 
Preliminary results from our ongoing research suggest 
that the PreserVe score may further be a useful tool 
for selection of patients suffering from hypercapnic re-
spiratory failure in arDs for treatment with ecco2r, 
representing a more sensible approach than the use of 
isolated criteria. our protocol, in an attempt to posi-
tion the use of ecco2r as a rescue therapy, further fa-
vored the inclusion of patients at the limit of lung pro-
tective mechanical ventilation, resulting in a median 
peak inspiratory pressure of 31 mbar and tidal volume 
of 5.2 ml/kg, corresponding to the original arDs 
network guidelines. as a consequence of low overall 
lung compliance the resulting median driving pressure 
was 25 mbar before initiation of ecco2r. given the 
most recent results including the study by amato et 
al. and referenced by Pettenuzzo and Del sorbo,6 that 
were published since the conclusion of our study, we 
agree that driving pressure (DP=Pplat-PeeP) should 
be considered in the inclusion criteria for ecco2r 
in mechanically ventilated patients in the future. We 
suggest considering ecco2r treatment in patients 
suffering from hypercapnic respiratory failure with 
pH≤7.25 and/or PaCO2≥9 kPa, where in mechanically 
ventilated patients an inability is reached to maintain 
VT≤6 mL/kg, Pplat≤30 mbar and DP≤15 mbar, and to 
base this expert decision on similar criteria as applied 
in considering ecMo therapy, possibly including the 
PreserVe score in arDs patients in order to avoid 
futile treatment.
in awake spontaneously breathing patients, mortality 
in our population was low but an eventual upgrade from 
ecco2r to full ecMo was necessary in a majority of 
patients. this is unsurprising considering that more pa-
tients in the respective group suffered from cystic fibro-
sis awaiting lung transplantation than other indications 
such as exacerbated chronic obstructive pulmonary dis-
ease. arguably, in these patients ecMo duration was 
reduced by up to 4.3 days. if using ecco2r to delay 
more invasive ECMO treatment results in a benefit for 
patients remains to be examined in future studies. Due 
to the low number of patients, our study does not allow 
to draw conclusions regarding success of bridge to re-
covery in awake spontaneously breathing patients such 
as patients with exacerbated chronic obstructive pulmo-
nary disease.
as Pettenuzzo and Del sorbo point out, spontane-
ous breathing increases variability in airway and in-
trathoracic pressure. even though NiV has the capac-
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the search for perfect supraglottic 
airway device: but I still haven’t found  
what I am looking for
Dear editor,
We read with interest the article by Kriege et al.1 and 
we would like to point out some comments regarding 
expectations and performances of supraglottic airway 
devices (saDs).
the rigorous method adopted by Kriege 1 for both 
data collection and analysis is clear proof of the ongo-
ity to add between 5 and 15 mbar of positive airway 
pressure, this would not be sufficient to counteract 
negative pleural pressure induced by forced inspira-
tory maneuvers in spontaneous breathing during re-
spiratory failure. We thus believe that the most likely 
explanation for our observation that target flow rates 
were more difficult to achieve in these patients is the 
association with negative inspiratory pressure during 
inspiration, while of course another factor is increased 
mobility in awake patients. We are not aware of previ-
ous studies reporting pleural pressure measurements 
during awake ecMo or ecco2r treatment. How-
ever, our subjective experience with ecco2r is simi-
lar to veno-venous ecMo treatment in awake versus 
in mechanically ventilated patients, supporting this 
hypothesis. Apart from blood flow rate, efficiency of 
the gas exchange membrane further determines sys-
tem efficiency. PvCO2, as determined in table iii in 
our article 2 as the sum of post membrane Pco2 and 
pre to post membrane DPco2 neither changed over 
the course of membrane system lifetime, nor between 
one and 48 hours of ecco2r treatment (P>0.05). the 
influence of membrane efficiency, PvCO2 and blood 
flow rate on post membrane PCO2 is complex,7 thus 
real-life data is needed to discern its value in a clinical 
setting. By demonstrating consistency in Pvco2 dur-
ing the later stages of treatment, our data suggests that 
post membrane co2 dependence on Pvco2 becomes 
less relevant and thus is a good surrogate measure-
ment of membrane efficiency during that period of 
treatment. technological development has since en-
abled measurement of co2 concentration within the 
membrane sweep gas outlet, further eliminating inac-
curacies introduced by difficulties in assessing total 
co2 content in blood samples, which will be reflected 
in future studies.
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